Typhlitis due to mucormycosis after chemotherapy in a patient with acute myeloid leukemia.
Yi
Hyon Seung
HS
Sym
Sun Jin
SJ
Park
Jinny
J
Cho
Eun Kyung
EK
Shin
Dong Bok
DB
Lee
Jae Hoon
JH
D000666:Amphotericin B / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000935:Antifungal Agents / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003561:Cytarabine / Q000008:administration & dosage / Q000009:adverse effects; D013505:Digestive System Surgical Procedures; D016984:Enterococcus faecium / Q000302:isolation & purification; D017809:Fatal Outcome; D005260:Female; D016908:Gram-Positive Bacterial Infections / Q000150:complications / Q000188:drug therapy; D006801:Humans; D015255:Idarubicin / Q000008:administration & dosage / Q000009:adverse effects; D015470:Leukemia, Myeloid, Acute / Q000150:complications / Q000188:drug therapy*; D008875:Middle Aged; D009091:Mucormycosis / Q000188:drug therapy / Q000209:etiology* / Q000601:surgery; D009503:Neutropenia / Q000139:chemically induced / Q000150:complications; D012220:Rhinitis / Q000150:complications; D012772:Shock, Septic / Q000209:etiology; D012852:Sinusitis / Q000150:complications; D053706:Typhlitis / Q000188:drug therapy / Q000209:etiology* / Q000601:surgery
D000900:Anti-Bacterial Agents; D000935:Antifungal Agents; D003561:Cytarabine; D000666:Amphotericin B; D015255:Idarubicin